Yun H, et al. Do Patients with Moderate or High Disease Activity Escalate RA Therapy According to Treat-to-Target Principles? Results from the ACR’s RISE Registry. ACR 2018, abstract 2856.
Bimekizumab bij actieve axSpA: effectiviteit en veiligheid over 52 weken
jan 2024 | Spondyloartritis